Visiongain states that the Global Hereditary Angioedema Market Set To Grow To $2.8bn By 2022

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Hereditary Angioedema Market Forecast 2018-2028: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze. Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies
Hereditary Angioedema is a disorder characterized by reoccurring phenomena of severe swelling. Limbs, face airway and intestinal tract are the common areas of the body that swells up in this condition. This report evaluates the global market of hereditary angioedema in regions such as North America, Latin America, Europe, Asia-Pacific and the Middle East and Africa. Furthermore, this report provides detailed overview of various medical hereditary angioedema segments such as drug class, route of administration and distribution channel.
The lead analyst of the report commented “Hereditary angioedema (HAE) is a rare disease and the diagnosis of HAE is challenging in children. Lack of awareness, diagnostic testing limitations, and communication difficulties along with the differential diagnosis of the symptoms of this disorder contribute to this challenge. Delay in diagnosis leads to sub-optimal treatment of symptoms and reduced quality of life.”

Leading companies featured in the report include BioCryst Pharmaceuticals, Inc., CSL Limited, iBio, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV, Santarus, Inc., Shire PLC

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever